<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430260</url>
  </required_header>
  <id_info>
    <org_study_id>HANDOK2010.07</org_study_id>
    <nct_id>NCT01430260</nct_id>
  </id_info>
  <brief_title>Omnaris Versus Levocetirizine Phase 4 Study</brief_title>
  <official_title>A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Handok Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This i a comparison of the efficacy ciclesonide nasal spray and levocetirizine, alone and in
      combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomized, open-label, three arm, parallel group, multi-center study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rTNSS</measure>
    <time_frame>2 weeks</time_frame>
    <description>change from baseline in the average of AM and PM patient assessed reflective TNSS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rTOSS</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reflective total ocular symptom sores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNSS</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient assessed individual TNSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANS</measure>
    <time_frame>2 weeks</time_frame>
    <description>Physician-assessed overall nasal signs and symptoms severity (PANS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RQLQ</measure>
    <time_frame>2 weeks</time_frame>
    <description>Rhinoconjunctivitis quality of life questionnaire (RQLQ)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>ciclesonide nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ciclesonide nasal spray, alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levocetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levocetirizine, alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide nasal spray &amp; Levocetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide nasal spray &amp; Levocetirizine in combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>200 ㎍ once daily</description>
    <arm_group_label>ciclesonide nasal spray</arm_group_label>
    <other_name>Omnaris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine</intervention_name>
    <description>5mg once daily</description>
    <arm_group_label>Levocetirizine</arm_group_label>
    <other_name>XYZAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide &amp; Levocetirizine</intervention_name>
    <description>Omnaris (ciclesonide) 200 ㎍ once daily
Levocetirizine 5mg once daily</description>
    <arm_group_label>Ciclesonide nasal spray &amp; Levocetirizine</arm_group_label>
    <other_name>Omnaris nasal spray</other_name>
    <other_name>XYZAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergic rhinitis patients aged ≥ 18 years (with a history of AR of 1 years or longer)

          -  Moderate to severe patient according to ARIA guideline

          -  To have a demonstrated positive skin prick test or other serologic tests to at least 1
             allergen.

          -  Subjects who complete the subject diary(S) at least 70%.

        Exclusion Criteria:

          -  Nasal pathology, including nasal polyps, clinically relevant respiratory tract
             malformations, recent nasal biopsy (within 60 days), nasal trauma, nasal surgery,
             atrophic rhinitis, rhinitis medicamentosa (within 60 days), asthma requiring
             corticosteroid treatment

          -  Hypersensitivity to corticosteroid and/or hydroxyzine

          -  Hypersensitivity to galactose intolerance, lapp lactase deficiency, glucose-galactose
             malabsorption

          -  A history of respiratory tract infection or disorder within 2 weeks of the screening
             visit or had a respiratory tract infection during baseline

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of β-agonists

          -  Treated with systemic corticosteroids (within 8 weeks of study initiation) or topical
             corticosteroids (&gt; 1% hydrocortisone, within 4 weeks of study initiation) or
             antibiotics (within 2 weeks of first visit)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moonhwa Park, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Handok Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>handok pharmaceuticals co. LTD</name>
      <address>
        <city>Seoul</city>
        <zip>135-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>ciclesonide</keyword>
  <keyword>levocetirizine</keyword>
  <keyword>allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

